MPS1 (also known as TTK), is a dual-specificity protein kinase and one of the main components of the spindle assembly checkpoint. Cancer cells heavily rely on MPS1 to cope with aneuploidy resulting from aberrant numbers of chromosomes and the kinase has been found to be upregulated in a large number of tumor types making it an attractive cancer target.
In this webinar we will focus on two aspects of our MPS1 drug discovery project.
The first aspect is the discovery of CCT289346, our preclinical candidate currently undergoing early clinical development. We will describe key medicinal chemistry challenges on route to the drug, particularly optimization of metabolic stability.
The second part of this webinar will be focused on our efforts to identify specific patient populations and tumor types, that may maximally benefit from treatment with MPS1 inhibitors. We will describe our work to identify such patient populations, leading to clinical hypotheses that are underpinned by in vivo data and that we have recently started to test in early clinical trials.
Attend this webinar to learn:
Multidimensional medicinal chemistry optimization approaches for the identification of drug candidates.
Hypothesis driven identification of clinical patient populations for MPS1 inhibitors.
Drug discovery in an academic setting.
Dr Swen Hoelder Team leader / Reader in Medicinal Chemistry and Drug Design,
Cancer Research UK Cancer Therapeutics Unit at the Institute of Cancer Research
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK